406 related articles for article (PubMed ID: 32248826)
1. 1.5 T MR-guided and daily adapted SBRT for prostate cancer: feasibility, preliminary clinical tolerability, quality of life and patient-reported outcomes during treatment.
Alongi F; Rigo M; Figlia V; Cuccia F; Giaj-Levra N; Nicosia L; Ricchetti F; Sicignano G; De Simone A; Naccarato S; Ruggieri R; Mazzola R
Radiat Oncol; 2020 Mar; 15(1):69. PubMed ID: 32248826
[TBL] [Abstract][Full Text] [Related]
2. Stereotactic body radiotherapy for oligometastatic castration sensitive prostate cancer using 1.5 T MRI-Linac: preliminary data on feasibility and acute patient-reported outcomes.
Mazzola R; Cuccia F; Figlia V; Rigo M; Nicosia L; Giaj-Levra N; Ricchetti F; Vitale C; Mantoan B; Di Paola G; De Simone A; Gurrera D; Sicignano G; Naccarato S; Ruggieri R; Alongi F
Radiol Med; 2021 Jul; 126(7):989-997. PubMed ID: 33835309
[TBL] [Abstract][Full Text] [Related]
3. Feasibility and safety of 1.5 T MR-guided and daily adapted abdominal-pelvic SBRT for elderly cancer patients: geriatric assessment tools and preliminary patient-reported outcomes.
Mazzola R; Figlia V; Rigo M; Cuccia F; Ricchetti F; Giaj-Levra N; Nicosia L; Vitale C; Sicignano G; De Simone A; Naccarato S; Ruggieri R; Alongi F
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2379-2397. PubMed ID: 32372146
[TBL] [Abstract][Full Text] [Related]
4. Rectal spacer hydrogel in 1.5T MR-guided and daily adapted SBRT for prostate cancer: dosimetric analysis and preliminary patient-reported outcomes.
Alongi F; Rigo M; Figlia V; Cuccia F; Giaj-Levra N; Nicosia L; Ricchetti F; Vitale C; Sicignano G; De Simone A; Naccarato S; Ruggieri R; Mazzola R
Br J Radiol; 2021 Jan; 94(1117):20200848. PubMed ID: 33095659
[TBL] [Abstract][Full Text] [Related]
5. Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer (mirage): a phase iii randomized trial.
Ma TM; Lamb JM; Casado M; Wang X; Basehart TV; Yang Y; Low D; Sheng K; Agazaryan N; Nickols NG; Cao M; Steinberg ML; Kishan AU
BMC Cancer; 2021 May; 21(1):538. PubMed ID: 33975579
[TBL] [Abstract][Full Text] [Related]
6. A Prospective Single-Arm Phase 2 Study of Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy for Prostate Cancer: Early Toxicity Results.
Bruynzeel AME; Tetar SU; Oei SS; Senan S; Haasbeek CJA; Spoelstra FOB; Piet AHM; Meijnen P; Bakker van der Jagt MAB; Fraikin T; Slotman BJ; van Moorselaar RJA; Lagerwaard FJ
Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):1086-1094. PubMed ID: 31419510
[TBL] [Abstract][Full Text] [Related]
7. A randomized phase II trial of MR-guided prostate stereotactic body radiotherapy administered in 5 or 2 fractions for localized prostate cancer (FORT).
Wolfe S; Diven MA; Marciscano AE; Zhou XK; Kishan AU; Steinberg ML; Miccio JA; Camilleri P; Nagar H
BMC Cancer; 2023 Sep; 23(1):923. PubMed ID: 37777738
[TBL] [Abstract][Full Text] [Related]
8. Functional imaging guided stereotactic ablative body radiotherapy (SABR) with focal dose escalation and bladder trigone sparing for intermediate and high-risk prostate cancer: study protocol for phase II safo trial.
Zapatero A; Castro P; Roch M; Carnero PR; Carroceda S; Rosciupchin AES; Hernández SH; Cogorno L; Iturriaga AG; García DB
Radiat Oncol; 2024 May; 19(1):54. PubMed ID: 38702761
[TBL] [Abstract][Full Text] [Related]
9. Intrafractional stability of MR-guided online adaptive SBRT for prostate cancer.
Schaule J; Chamberlain M; Wilke L; Baumgartl M; Krayenbühl J; Zamburlini M; Mayinger M; Andratschke N; Tanadini-Lang S; Guckenberger M
Radiat Oncol; 2021 Sep; 16(1):189. PubMed ID: 34565439
[TBL] [Abstract][Full Text] [Related]
10. Impact of hydrogel peri-rectal spacer insertion on prostate gland intra-fraction motion during 1.5 T MR-guided stereotactic body radiotherapy.
Cuccia F; Mazzola R; Nicosia L; Figlia V; Giaj-Levra N; Ricchetti F; Rigo M; Vitale C; Mantoan B; De Simone A; Sicignano G; Ruggieri R; Cavalleri S; Alongi F
Radiat Oncol; 2020 Jul; 15(1):178. PubMed ID: 32698843
[TBL] [Abstract][Full Text] [Related]
11. Online Adaptive MR-Guided Ultrahypofractionated Radiotherapy of Prostate Cancer on a 1.5 T MR-Linac: Clinical Experience and Prospective Evaluation.
Potkrajcic V; Gani C; Fischer SG; Boeke S; Niyazi M; Thorwarth D; Voigt O; Schneider M; Mönnich D; Kübler S; Boldt J; Hoffmann E; Paulsen F; Mueller AC; Wegener D
Curr Oncol; 2024 May; 31(5):2679-2688. PubMed ID: 38785484
[TBL] [Abstract][Full Text] [Related]
12. High-quality Linac-based Stereotactic Body Radiation Therapy with Flattening Filter Free Beams and Volumetric Modulated Arc Therapy for Low-Intermediate Risk Prostate Cancer. A Mono-institutional Experience with 90 Patients.
D'Agostino G; Franzese C; De Rose F; Franceschini D; Comito T; Villa E; Alongi F; Liardo R; Tomatis S; Navarria P; Mancosu P; Reggiori G; Cozzi L; Scorsetti M
Clin Oncol (R Coll Radiol); 2016 Dec; 28(12):e173-e178. PubMed ID: 27389021
[TBL] [Abstract][Full Text] [Related]
13. Linac-based stereotactic body radiation therapy for low and intermediate-risk prostate cancer : Long-term results and factors predictive for outcome and toxicity.
Franzese C; Badalamenti M; Di Brina L; D'Agostino G; Franceschini D; Comito T; Clerici E; Navarria P; Reggiori G; Mancosu P; Tomatis S; Scorsetti M
Strahlenther Onkol; 2020 Jul; 196(7):608-616. PubMed ID: 32303782
[TBL] [Abstract][Full Text] [Related]
14. Accumulated bladder wall dose is correlated with patient-reported acute urinary toxicity in prostate cancer patients treated with stereotactic, daily adaptive MR-guided radiotherapy.
Willigenburg T; van der Velden JM; Zachiu C; Teunissen FR; Lagendijk JJW; Raaymakers BW; de Boer JCJ; van der Voort van Zyp JRN
Radiother Oncol; 2022 Jun; 171():182-188. PubMed ID: 35489444
[TBL] [Abstract][Full Text] [Related]
15. Prostate volume variation during 1.5T MR-guided adaptive stereotactic body radiotherapy (SBRT) and correlation with treatment toxicity.
Nicosia L; Ravelli P; Rigo M; Giaj-Levra N; Mazzola R; Pastorello E; Ricchetti F; Allegra AG; Ruggieri R; Alongi F
Radiother Oncol; 2024 Jan; 190():110043. PubMed ID: 38056694
[TBL] [Abstract][Full Text] [Related]
16. Magnetic Resonance Imaging-Guided vs Computed Tomography-Guided Stereotactic Body Radiotherapy for Prostate Cancer: The MIRAGE Randomized Clinical Trial.
Kishan AU; Ma TM; Lamb JM; Casado M; Wilhalme H; Low DA; Sheng K; Sharma S; Nickols NG; Pham J; Yang Y; Gao Y; Neylon J; Basehart V; Cao M; Steinberg ML
JAMA Oncol; 2023 Mar; 9(3):365-373. PubMed ID: 36633877
[TBL] [Abstract][Full Text] [Related]
17. Magnetic Resonance-guided Stereotactic Radiotherapy for Localized Prostate Cancer: Final Results on Patient-reported Outcomes of a Prospective Phase 2 Study.
Tetar SU; Bruynzeel AME; Oei SS; Senan S; Fraikin T; Slotman BJ; Moorselaar RJAV; Lagerwaard FJ
Eur Urol Oncol; 2021 Aug; 4(4):628-634. PubMed ID: 32536573
[TBL] [Abstract][Full Text] [Related]
18. Linac-based versus MR-guided SBRT for localized prostate cancer: a comparative evaluation of acute tolerability.
Nicosia L; Mazzola R; Rigo M; Giaj-Levra N; Pastorello E; Ricchetti F; Vitale C; Figlia V; Cuccia F; Ruggieri R; Alongi F
Radiol Med; 2023 May; 128(5):612-618. PubMed ID: 37055672
[TBL] [Abstract][Full Text] [Related]
19. Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: early results.
Aluwini S; van Rooij P; Hoogeman M; Kirkels W; Kolkman-Deurloo IK; Bangma C
Radiat Oncol; 2013 Apr; 8():84. PubMed ID: 23570391
[TBL] [Abstract][Full Text] [Related]
20. Safety and Tolerability of Online Adaptive High-Field Magnetic Resonance-Guided Radiotherapy.
Westerhoff JM; Daamen LA; Christodouleas JP; Blezer ELA; Choudhury A; Westley RL; Erickson BA; Fuller CD; Hafeez S; van der Heide UA; Intven MPW; Kirby AM; Lalondrelle S; Minsky BD; Mook S; Nowee ME; Marijnen CAM; Orrling KM; Sahgal A; Schultz CJ; Faivre-Finn C; Tersteeg RJHA; Tree AC; Tseng CL; Schytte T; Silk DM; Eggert D; Luzzara M; van der Voort van Zyp JRN; Verkooijen HM; Hall WA
JAMA Netw Open; 2024 May; 7(5):e2410819. PubMed ID: 38691356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
